Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.
about
Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection MethodsProfile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infectionsAntibiotic resistance in the wild: an eco-evolutionary perspectiveEpidemiology and Outcomes of Complicated Skin and Soft Tissue Infections among Inpatients in Southern China from 2008 to 2013Polyamino-Isoprenic Derivatives Block Intrinsic Resistance of P. aeruginosa to Doxycycline and Chloramphenicol In VitroEvaluation of the Interaction between the Poincianella pyramidalis (Tul.) LP Queiroz Extract and Antimicrobials Using Biological and Analytical ModelsNationwide Surveillance of Clinical Carbapenem-resistant Enterobacteriaceae (CRE) Strains in China.A High-Content, Phenotypic Screen Identifies Fluorouridine as an Inhibitor of Pyoverdine Biosynthesis and Pseudomonas aeruginosa VirulencePlazomicin: an investigational therapy for the treatment of urinary tract infections.Prevalence of Klebsiella pneumoniae strains producing carbapenemases and increase of resistance to colistin in an Italian teaching hospital from January 2012 To December 2014Increased prevalence of carbapenem resistant Enterobacteriaceae in hospital setting due to cross-species transmission of the bla NDM-1 element and clonal spread of progenitor resistant strains.Genetic Evidence for O-Specific Antigen as Receptor of Pseudomonas aeruginosa Phage K8 and Its Genomic Analysis.Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam.Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial DominanceColistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.Altered Outer Membrane Transcriptome Balance with AmpC Overexpression in Carbapenem-Resistant Enterobacter cloacaeSynergistic combinations of polymyxins.Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control.Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) in brain and spinal cord injury patients: potential for prolonged colonization.Functional Site Discovery in a Sulfur Metabolism Enzyme by Using Directed Evolution.Prevalence and risk factors associated with colonization and infection of extensively drug-resistant Pseudomonas aeruginosa: a systematic review.Antibiotics Clinical Development and Pipeline.Progress in Understanding the Genetic Information and Biosynthetic Pathways behind Amycolatopsis Antibiotics, with Implications for the Continued Discovery of Novel Drugs.The respiratory threat posed by multidrug resistant Gram-negative bacteria.Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in Greece: an extended review (2000-2015).Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments.Emerging drugs for nosocomial pneumonia.Colistin: still a lifesaver for the 21st century?Efficacy and Safety of High Loading Dose of Colistin in Multidrug-Resistant Acinetobacter baumannii: A Prospective Cohort Study.Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study.Evaluation of two automated systems for colistin susceptibility testing of carbapenem-resistant Acinetobacter baumannii clinical isolates.Changing trends in the aetiology, treatment and outcomes of bloodstream infection occurring in the first year after solid organ transplantation: a single-centre prospective cohort study.Potential Toxicity of Polymyxins in Human Lung Epithelial Cells.Epidemiological surveillance of multidrug-resistant gram-negative bacteria in a solid organ transplantation department.Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae.Over expression of AdeABC and AcrAB-TolC efflux systems confers tigecycline resistance in clinical isolates of Acinetobacter baumannii and Klebsiella pneumoniae.Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa.Emergence of Carbapenem-Resistant Klebsiella pneumoniae: Progressive Spread and Four-Year Period of Observation in a Cardiac Surgery Division.
P2860
Q26744583-7D4384CA-BBE4-4532-B649-C5AD452D2539Q27001490-B7BECF05-D459-460E-B762-30E7A2114E21Q28075650-FB6B25EF-C958-48D9-B7B6-B767D4F3938CQ28550407-074C6CD0-DEBC-4741-887B-B009909AC897Q28551861-27CD9E56-43C5-4F56-9BF8-C4DC1916D99CQ28552193-79F8FBD8-8447-42FE-B0A4-B6862FE83FE2Q33715837-E5107DA1-41AA-41AB-880E-BA12569958E5Q34539031-F8A455AF-DCAA-4B4C-BADF-704E4FA11C98Q34673393-A5B6747F-5542-445E-9425-2C9756888683Q35676151-EECFF101-7401-4CD6-8B36-AA2A9F70F119Q35746715-2D86E9EF-D31D-4426-ABE2-B4968EB36BF4Q35955662-C2028859-FD0C-4200-9599-5AE610041244Q36020757-907AB02D-576D-4D4F-8C9A-D5F8254DB671Q36076066-2971E5BD-EF35-487B-8ECC-4285135AE6CDQ36290841-CC307B16-63E4-4495-B0D6-CF268172E465Q37528489-D5AE3F56-80F9-4DB7-AD9E-8E39B4557311Q37586960-8692B4B7-470B-458D-A93D-291BAEE40753Q38296151-1786A3CF-B588-4E9B-80F5-F3BEBB2A6EA5Q38306504-E8412AB3-64A9-4CC6-A2DD-B7C1D4BFAF14Q38377915-3C5DDF1D-545E-4728-BA40-16E396463669Q38437117-F087638B-994E-492C-A988-0CF160B765F4Q38543852-320E6F52-F896-46C3-A2EC-8062341BD099Q38544966-7AB2501C-2B6A-4CB9-889A-D1BDD6C069C6Q38616773-D7B71BBC-A69A-4B6E-B746-8556271C5B7EQ38662137-49BD5E8D-0317-412B-A4BF-1EA280520812Q38672110-DDA9AEB5-0AB5-4ADB-9680-AF45ACF31EE9Q38749988-6DCCA811-A0E5-4993-A6D0-2768F06E1DE0Q38878167-4431ADD8-9934-40E2-8B08-58621C0BF810Q38940249-19AED235-C920-4CAC-AF19-4E9D256A5F98Q40088667-F72888AA-611D-4438-8F4A-40A36F0FF6ADQ40146757-7357DEF0-2A07-47D5-8F90-A02BEB657D80Q40176183-9C097123-123E-4FD2-BBA9-3196C9007783Q40214475-174F0EAA-4AFC-42DB-B433-A465F97B36F6Q40248118-C3F3DC3C-81C9-4B10-BE66-D4D5BD4A2550Q40311528-11C917B1-20B9-4089-8538-4CF10C275B9AQ40328540-2E224A7A-22F2-4B56-8343-A0B69309ECA9Q40669465-66702E39-D37A-4184-9746-548583B2DC87Q40697349-970CD831-7650-4974-971F-A48C7E63D8C5Q40698278-896F1340-72C2-4836-B5BA-8483302D2714Q40745160-97C09EFA-B572-48AD-841A-7DE65474E273
P2860
Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Multidrug-resistant and extens ...... erging therapeutic approaches.
@ast
Multidrug-resistant and extens ...... erging therapeutic approaches.
@en
type
label
Multidrug-resistant and extens ...... erging therapeutic approaches.
@ast
Multidrug-resistant and extens ...... erging therapeutic approaches.
@en
prefLabel
Multidrug-resistant and extens ...... erging therapeutic approaches.
@ast
Multidrug-resistant and extens ...... erging therapeutic approaches.
@en
P2860
P921
P1476
Multidrug-resistant and extens ...... merging therapeutic approaches
@en
P2093
Helen Giamarellou
Ilias Karaiskos
P2860
P304
P356
10.1517/14656566.2014.914172
P407
P577
2014-04-28T00:00:00Z